Table 2.
Longitudinal Early Clinical Validation Patient Data.
| Primary Disease | Treatment | Response | Size | Age | Sex |
|---|---|---|---|---|---|
| Colorectal Adenocarcinoma | FOLFOX + Bevacizumab | Regression | 9 cm | 60 | M |
| Pancreatic Neuroendocrine | Temozolomide + Capecitabine | Stable | 2.4 cm | 61 | M |
| Pancreatic Adenocarcinoma | Capecitabine + Oxaliplatin | Stable | 1.6 cm | 54 | M |
| Colorectal Adenocarcinoma | Irinotecan + Bevacizumab | Regression | 4.3 cm | 52 | M |
| Pancreatic Adenocarcinoma | Capecitabine + Oxaliplatin | Progression | 2.6 cm | 70 | F |
| Colorectal Adenocarcinoma | RRx-001 | Progression | 2.2 cm | 68 | M |
| Pancreatic Neuroendocrine | Everolimus + Octreotide + Embolization | Progression | 9.5 cm | 52 | M |
| Pancreatic Neuroendocrine | Everolimus | Stable | 2 cm | 54 | F |
| Pancreatic Adenocarcinoma | Gem-Abraxane | Stable | 1.2 cm | 72 | F |